Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS)
CNY 31.9
(0.73%)
CNY 31.9
(0.73%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 8.22 Billion | 8.24 Billion | 6.9 Billion | 6.6 Billion | 6.99 Billion | 6.35 Billion |
| Cost of Revenue | 4.63 Billion | 4.95 Billion | 4.15 Billion | 4.02 Billion | 4.04 Billion | 3.72 Billion |
| Gross Profit | 3.59 Billion | 3.29 Billion | 2.75 Billion | 2.57 Billion | 2.94 Billion | 2.63 Billion |
| Operating Expenses | 2.52 Billion | 2.57 Billion | 2.14 Billion | 1.97 Billion | 2.38 Billion | 2.15 Billion |
| Selling, General and Administrative Expenses | 2.48 Billion | 2.04 Billion | 1.64 Billion | 1.54 Billion | 1.91 Billion | 1.76 Billion |
| Research and Development Expenses | 184.62 Million | 153.14 Million | 161.05 Million | 149.2 Million | 133.36 Million | 100.92 Million |
| Other Expenses | -218.66 Million | 367.72 Million | 337.84 Million | 289.08 Million | 332.7 Million | -919.06 Thousand |
| Cost and Expenses | 7.12 Billion | 7.52 Billion | 6.29 Billion | 6 Billion | 6.42 Billion | 5.88 Billion |
| Operating Income | 1.09 Billion | 980.04 Million | 866.67 Million | 785.17 Million | 759.02 Million | 641.54 Million |
| Interest Expense | 37.88 Million | 10.26 Million | 2.93 Million | 6660.00 | 4.89 Million | 11.38 Million |
| Income Tax Expense | 126.65 Million | 106.93 Million | 85.92 Million | 88.39 Million | 107.78 Million | 72.84 Million |
| Earnings before Tax | 1.09 Billion | 980.18 Million | 872.8 Million | 768.05 Million | 743.14 Million | 640.62 Million |
| Net Income | 986.7 Million | 861.79 Million | 769.14 Million | 661.7 Million | 625.56 Million | 561.67 Million |
| Earnings Per Share Basic | 1.28 | 1.12 | 1.00 | 0.86 | 0.81 | 0.73 |
| Earnings Per Share Diluted | 1.28 | 1.11 | 1.00 | 0.86 | 0.81 | 0.73 |
| Weighted Average Shares Outstanding | 770.86 Million | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million |
| Weighted Average Shares Outstanding (Diluted) | 770.86 Million | 776.39 Million | 768.87 Million | 768.87 Million | 768.87 Million | 769.42 Million |
| Gross Margin | 0.44 | 0.40 | 0.40 | 0.39 | 0.42 | 0.41 |
| EBIT Margin | 0.12 | 0.14 | 0.14 | 0.13 | 0.12 | 0.11 |
| Profit Margin | 0.12 | 0.10 | 0.11 | 0.10 | 0.09 | 0.09 |
| EBITDA | 971.82 Million | 1.1 Billion | 991.27 Million | 878.91 Million | 846.18 Million | 728.15 Million |
| Earnings Before Tax Margin | 0.13 | 0.12 | 0.13 | 0.12 | 0.11 | 0.10 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 1.64 Billion | 1.85 Billion | 2.06 Billion | 2.4 Billion | 8.14 Billion | 1.7 Billion |
| Cost of Revenue | 878.27 Million | 990.52 Million | 1.01 Billion | 1.42 Billion | 4.66 Billion | 1.02 Billion |
| Gross Profit | 767.91 Million | 867.5 Million | 1.05 Billion | 977.52 Million | 3.48 Billion | 683.01 Million |
| Operating Expenses | 617.81 Million | 625.42 Million | 696.94 Million | 942.89 Million | 2.72 Billion | 531.87 Million |
| Selling, General and Administrative Expenses | 933.36 Million | 591.34 Million | 670.76 Million | 792.44 Million | - | 635.02 Million |
| Research and Development Expenses | 52.14 Million | 19.76 Million | 24.73 Million | 95.77 Million | - | 34.46 Million |
| Other Expenses | -367.68 Million | -14.31 Million | -1.44 Million | -54.67 Million | -64.23 Million | -509 Thousand |
| Cost and Expenses | 1.49 Billion | 1.61 Billion | 1.7 Billion | 2.36 Billion | 7.38 Billion | 1.55 Billion |
| Operating Income | 171.58 Million | 242.07 Million | 355.41 Million | 34.62 Million | 758.95 Million | 153.05 Million |
| Interest Expense | 11.73 Million | 11.05 Million | 6.83 Million | 8.02 Million | 35.85 Million | 10.82 Million |
| Income Tax Expense | 33.8 Million | 39.32 Million | 57.15 Million | 7.39 Million | 126.65 Million | 24.99 Million |
| Earnings before Tax | 175.76 Million | 258.13 Million | 367.93 Million | 50.78 Million | 800.78 Million | 152.54 Million |
| Net Income | 146.13 Million | 270.39 Million | 387.32 Million | 128.51 Million | 986.7 Million | 135.7 Million |
| Earnings Per Share Basic | 0.19 | 0.35 | 0.50 | 0.17 | - | 0.18 |
| Earnings Per Share Diluted | 0.19 | 0.35 | 0.50 | 0.17 | - | 0.18 |
| Weighted Average Shares Outstanding | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million |
| Weighted Average Shares Outstanding (Diluted) | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million | 768.87 Million |
| Gross Margin | 0.47 | 0.47 | 0.51 | 0.41 | 0.43 | 0.40 |
| EBIT Margin | 0.11 | 0.15 | 0.22 | 0.03 | - | 0.11 |
| Profit Margin | 0.09 | 0.15 | 0.19 | 0.05 | 0.12 | 0.08 |
| EBITDA | 187.5 Million | 273.62 Million | 454.91 Million | 68.65 Million | - | 181.56 Million |
| Earnings Before Tax Margin | 0.10 | 0.13 | 0.17 | 0.01 | 0.09 | 0.09 |
KRDXF
ALEMG
5243
SGRP
STEV
7161